Cargando…
The Genetic Basis of Moyamoya Disease
Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766392/ https://www.ncbi.nlm.nih.gov/pubmed/34529262 http://dx.doi.org/10.1007/s12975-021-00940-2 |
_version_ | 1784634519628808192 |
---|---|
author | Mertens, R. Graupera, M. Gerhardt, H. Bersano, A. Tournier-Lasserve, E. Mensah, M. A. Mundlos, S. Vajkoczy, P. |
author_facet | Mertens, R. Graupera, M. Gerhardt, H. Bersano, A. Tournier-Lasserve, E. Mensah, M. A. Mundlos, S. Vajkoczy, P. |
author_sort | Mertens, R. |
collection | PubMed |
description | Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral angiography. These pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive screening and possibly the development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only. |
format | Online Article Text |
id | pubmed-8766392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-87663922022-02-02 The Genetic Basis of Moyamoya Disease Mertens, R. Graupera, M. Gerhardt, H. Bersano, A. Tournier-Lasserve, E. Mensah, M. A. Mundlos, S. Vajkoczy, P. Transl Stroke Res Review Article Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral angiography. These pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive screening and possibly the development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only. Springer US 2021-09-16 2022 /pmc/articles/PMC8766392/ /pubmed/34529262 http://dx.doi.org/10.1007/s12975-021-00940-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Mertens, R. Graupera, M. Gerhardt, H. Bersano, A. Tournier-Lasserve, E. Mensah, M. A. Mundlos, S. Vajkoczy, P. The Genetic Basis of Moyamoya Disease |
title | The Genetic Basis of Moyamoya Disease |
title_full | The Genetic Basis of Moyamoya Disease |
title_fullStr | The Genetic Basis of Moyamoya Disease |
title_full_unstemmed | The Genetic Basis of Moyamoya Disease |
title_short | The Genetic Basis of Moyamoya Disease |
title_sort | genetic basis of moyamoya disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766392/ https://www.ncbi.nlm.nih.gov/pubmed/34529262 http://dx.doi.org/10.1007/s12975-021-00940-2 |
work_keys_str_mv | AT mertensr thegeneticbasisofmoyamoyadisease AT grauperam thegeneticbasisofmoyamoyadisease AT gerhardth thegeneticbasisofmoyamoyadisease AT bersanoa thegeneticbasisofmoyamoyadisease AT tournierlasservee thegeneticbasisofmoyamoyadisease AT mensahma thegeneticbasisofmoyamoyadisease AT mundloss thegeneticbasisofmoyamoyadisease AT vajkoczyp thegeneticbasisofmoyamoyadisease AT mertensr geneticbasisofmoyamoyadisease AT grauperam geneticbasisofmoyamoyadisease AT gerhardth geneticbasisofmoyamoyadisease AT bersanoa geneticbasisofmoyamoyadisease AT tournierlasservee geneticbasisofmoyamoyadisease AT mensahma geneticbasisofmoyamoyadisease AT mundloss geneticbasisofmoyamoyadisease AT vajkoczyp geneticbasisofmoyamoyadisease |